Clinical trial
BMS-247550 in Treating Patients With Stage IV Melanoma
NCT00036764 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00036764 |
|---|---|
| Title | BMS-247550 in Treating Patients With Stage IV Melanoma |
| Official title | A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | ixabepilone, pharmacogenomic studies, laboratory biomarker analysis |
| Enrollment | 88 |
| Start date | Feb 1, 2002 |
| Primary completion | Aug 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: